Publications

Precision Antimicrobial Therapeutics: the path of least resistance? Nature Biofilms and Microbiomes. 2018; 4: 4.

Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Proc Natl Acad Sci U S A. 2018; 115(12): E2819-E2828. 

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Expert Opin Drug Discov. 2017; 12(7): 711-731.

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature. 2017; 546(7659): 528-32.

Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Sci Adv. 2017; 3(2): e1601944.

Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. J Med Chem. 2016; 59(20): 9390-9408.

Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. Expert Opin Ther Pat. 2016; 26(2): 175-97.

Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Chem Med Chem. 2016; 11(4): 367-73.

A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug resistant uropathogenic Escherichia coli ST131, J Inf Dis. 2013; 208(6): 921-8.

Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem. 2012; 55(8): 3945-59.

Treatment and Prevention of Urinary Tract Infection with Orally Active Mannoside FimH Inhibitors. Sci Trans Med. 2011; 3(109): 1-10.

Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem. 2010; 53(12): 4779-92.